Finding dependencies that cancer cells rely on
The research combines genomic and other biological data with laboratory screening and disease models. It identifies and validates lineage dependencies before designing molecules intended to disrupt them. These are investigational medicines, with the lead programs moving through discovery and early development.
Building a portfolio from licensed research
A separate agreement announced the same day grants exclusive global rights to multiple preclinical oncology programs discovered by Eisai and its affiliates. Those assets provide a starting portfolio across distinct targets and pathways. The company operates in the United States, Japan and China.
Where the funding goes
- Discovery and early clinical development of lead programs